SPRY2, sprouty RTK signaling antagonist 2, 10253

N. diseases: 111; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.070 Biomarker disease BEFREE Taken together, our findings demonstrate the critical role of miR-330-5p in promoting HCC progression via targeting SPRY2 to activate MAPK/ERK signaling, which may provide a novel and promising prognostic marker and therapeutic target for HCC. 30464168 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.070 Biomarker disease BEFREE Therefore, the miR‑27b/Spry2 axis may be considered a potential therapeutic target for HCC. 26846382 2016
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.070 AlteredExpression disease BEFREE SPRY1 expression was also found to be significantly up-regulated in the cases without underlying cirrhosis compared with those with cirrhosis (log fold change of 0.35 and -0.02, respectively, P < 0.05), whereas SPRY2 expression was significantly lower in the cases with advanced HCC (log fold change of -0.12 and -0.52 in early and advanced stages, respectively, P < 0.05) and in those with angiolymphatic invasion (log fold change of -0.47 and -0.16 in the presence and absence thereof, P < 0.05). 21932411 2012
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.070 Biomarker disease BEFREE Multivariate analysis further established Spry2 as an independent predictor of postoperative recurrence in HCC patients (HR=1.47; 95% CI, 1.02-2.08; P=0.037). 22484587 2012
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.070 Biomarker disease BEFREE The human HLE hepatocellular carcinoma (HCC) cell line, stably overexpressing AKT, was transfected with Spry2Y55F to study the molecular mechanisms underlying hepatocarcinogenesis driven by Spry2 loss. 22617155 2012
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.070 AlteredExpression disease LHGDN Our study provides evidence that inhibition of Spry activity cooperates with other oncogenes to promote liver cancer in mouse models, and Spry2 may function as a candidate tumor suppressor for HCC development in vivo. 18214995 2008
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.070 Biomarker disease BEFREE Our study provides evidence that inhibition of Spry activity cooperates with other oncogenes to promote liver cancer in mouse models, and Spry2 may function as a candidate tumor suppressor for HCC development in vivo. 18214995 2008
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.070 Biomarker disease BEFREE Our study clearly indicates a role for Spry2 in hepatocellular carcinoma, and an understanding of the regulatory controls of its expression could provide new means of regulating the angiogenic switch in this hypervascular tumor, thereby potentially controlling tumor growth. 16489004 2006
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.070 AlteredExpression disease LHGDN Our study clearly indicates a role for Spry2 in hepatocellular carcinoma, and an understanding of the regulatory controls of its expression could provide new means of regulating the angiogenic switch in this hypervascular tumor, thereby potentially controlling tumor growth. 16489004 2006